Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 33-40

  Krishnan, Suma M ^a,c   Stark, Jeffrey G ^b  

^a New River Pharmaceuticals   (United States)

^b CEDRA Corporation   (United States)

^c NONE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Dextroamphetamine; Lisdexamfetamine dimesylate; Pharmacokinetics

Indexed keywords

DEXAMPHETAMINE; LISDEXAMFETAMINE;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; STATISTICAL ANALYSIS; STEADY STATE; TACHYCARDIA;

EID: 38549118950     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X242737     Document Type: Article

References (16)

1. American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000;105:1158-70
2. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997;36:85S-121
3. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005;35:245-56
4. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-57
5. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48
6. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:77-97
7. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-18
8. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
9. Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spect 2005;10:6-15
10. Boyle L, Moncrief S, Krishnan S. Pharmacokinetics of NRP 104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rats. Abstract presented at the 46th Annual Meeting of the New Clinical Drug Evaluation Unit; June 12-15, 2006; Boca Raton, FL, USA
11. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2007;29:450-63
12. Findling RL, Childress AC, Krishnan S, et al. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/ hyperactivity disorder. Poster presented at the 160th Annual Meeting of the American Psychological Association; May 19-24, 2007; San Diego, CA, USA
13. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6
14. Krishnan S, Ermer JC, Kehner G. Effect of food on lisdexamfetamine dimesylate (LDX; NRP104) pharmacokinetics. Abstract presented at the US Psychiatric and Mental Health 19th Annual Congress; November 15-19, 2006; New Orleans, LA, USA
15. Auiler JF, Liu K, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med Res Opin 2002;18:311-6
16. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-39